Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications

Area of Science:

• Coordination Chemistry
• Biochemistry
• Cancer Research

Background:

• Ruthenium(ii) polypyridyl complexes (RPCs) exhibit significant interest due to their DNA-binding affinity, photophysical characteristics, and demonstrated anticancer properties.
• DNA is a primary target for RPCs, with their role as photosensitizers in photodynamic therapy highlighting DNA damage as a crucial biological consequence.

Purpose of the Study:

• To review recent advancements in designing RPCs as pharmacological DNA-targeting agents.
• To elucidate the impact of RPCs on the DNA damage response (DDR) and the nature of induced DNA lesions.
• To examine the correlation between RPC binding modes, DDR pathway activation, and cancer cell fate for therapeutic applications.

Main Methods:

• Literature review of recent studies on RPC design and their biological effects.
• Analysis of data linking RPC-induced DNA lesions to specific DDR pathways.
• Examination of cell fate outcomes in human cancer cell lines treated with RPCs.

Main Results:

• RPCs effectively target DNA, leading to DNA damage and subsequent activation of the DDR.
• Different RPC binding modes correlate with specific DDR pathway engagement.
• The interplay between RPCs, DDR, and cell fate offers therapeutic potential in cancer treatment.

Conclusions:

• RPCs represent a versatile class of compounds for DNA-targeting cancer therapy.
• Understanding the RPC-DDR interaction is key to optimizing anticancer efficacy and selectivity.
• Combination strategies involving RPCs and DDR inhibitors may enhance cancer treatment outcomes.